Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

BACKGROUND We studied whether inflammation after myocardial infarction (MI) is a risk factor for recurrent coronary events and whether randomized treatment with pravastatin reduces that risk. METHODS AND RESULTS A nested case-control design was used to compare C-reactive protein (CRP) and serum amyloid A (SAA) levels in prerandomization blood samples from 391 participants in the Cholesterol and Recurrent Events (CARE) trial who subsequently developed recurrent nonfatal MI or a fatal coronary event (cases) and from an equal number of age- and sex-matched participants who remained free of these events during follow-up (control subjects). Overall, CRP and SAA were higher among cases than control subjects (for CRP P=0.05; for SAA P=0.006) such that those with levels in the highest quintile had a relative risk (RR) of recurrent events 75% higher than those with levels in the lowest quintile (for CRP RR= 1.77, P=0.02; for SAA RR= 1.74, P=0.02). The study group with the highest risk was that with consistent evidence of inflammation (elevation of both CRP and SAA) who were randomly assigned to placebo (RR=2.81, P=0.007); this risk estimate was greater than the product of the individual risks associated with inflammation or placebo assignment alone. In stratified analyses, the association between inflammation and risk was significant among those randomized to placebo (RR=2.11, P=0.048) but was attenuated and nonsignificant among those randomized to pravastatin (RR=1.29, P=0.5). CONCLUSIONS Evidence of inflammation after MI is associated with increased risk of recurrent coronary events. Therapy with pravastatin may decrease this risk, an observation consistent with a nonlipid effect of this agent.

[1]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[2]  J. Sipe,et al.  Analytical Evaluation of Particle-Enhanced Immunonephelometric Assays for C-Reactive Protein, Serum Amyloid a and Mannose-Binding Protein in Human Serum , 1998, Annals of clinical biochemistry.

[3]  R J Glynn,et al.  C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. , 1998, Circulation.

[4]  P. Ridker.  Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? , 1998, Circulation.

[5]  P. Ridker,et al.  Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. , 1998, Circulation.

[6]  L H Kuller,et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[7]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[8]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[9]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[10]  K. Silver,et al.  β3-adrenoceptor gene variant in obesity and insulin resistance , 1996, The Lancet.

[11]  Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin , 1996, The Lancet.

[12]  B. Buckley,et al.  Statins do more than just lower cholesterol , 1996, The Lancet.

[13]  L. Kuller,et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[14]  Y. Shimada,et al.  Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. , 1996, Immunopharmacology.

[15]  E. Donetti,et al.  Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. , 1996, Cardiology.

[16]  David J. Weatherall,et al.  Oxford textbook of medicine , 1996 .

[17]  N. Hosomi,et al.  Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. , 1996, Atherosclerosis.

[18]  I. Sartori.  Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris , 1996 .

[19]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[20]  G. Rogler,et al.  Effects of flwastatin on growth of porcine and human vascular smooth muscle cells in vitro , 1995 .

[21]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[22]  L. Howes,et al.  Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. , 1995, The American journal of cardiology.

[23]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[24]  M. Casl,et al.  Serum Amyloid a Protein in Patients with Acute Myocardial Infarction , 1995, Annals of clinical biochemistry.

[25]  A. Yeung,et al.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.

[26]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[27]  G. Rogler,et al.  Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. , 1995, The American journal of cardiology.

[28]  M. Aviram,et al.  Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. , 1994, British journal of clinical pharmacology.

[29]  P. Sever,et al.  Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis , 1994, European journal of clinical investigation.

[30]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[31]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[32]  Koji Suzuki,et al.  Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia , 1993, American journal of hematology.

[33]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[34]  M. Pfeffer,et al.  Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) , 1991, The American journal of cardiology.

[35]  W. Weintraub,et al.  Elevation of C-reactive protein in "active" coronary artery disease. , 1990, The American journal of cardiology.

[36]  A. Maseri,et al.  C-Reactive Protein in Myocardial Infarction and Ischaemia , 1982 .